Skip to main content
. 2024 Aug 14;86(10):5938–5946. doi: 10.1097/MS9.0000000000002478

Table 1.

The strength and credibility of the previously discussed studies concerning CRISPR/cas9 technique for treatment of SCD

Study ID Study method Strength and credibility
Sharma et al., 202353 Multicenter, phase 1–2 clinical study The strengths of the study are Innovative technology, Comprehensive screening, rigorous pre-clinical tests, comprehensive monitoring, and ethical oversight. The limitations include limited participants, selection bias, short follow-up, and manufacturing and logistic challenges.
Khlidj, 202354 literature review The strengths of the study include a comprehensive overview, broad data sources, an empirical focus to provide concrete evidence, and a longitudinal perspective. The limitations include scope being limited to existing data, no new data has been incorporated, selection bias, publication bias, and depth of analysis on methodologies.
Demirci et al., 202155 narrative review The strengths of the study include a comprehensive overview of the study which includes the current and relevant information, clear presentation, practical focus, and interdisciplinary insights. The limitations include limited participant data, selection bias, and short follow-up.
Park & Bao, 202156 Pre-clinical experimental study The strength of the study includes the translation potential as it uses nonhuman primates, an Innovative approach of CRISPR technology, and evaluates multiple aspects. The limitation of the study is its pre-clinical nature, off-target effects, and durability of gene editing.
Huang, 202357 Clinical trial study The strengths are the innovative treatment approach of gene editing, targeted gene editing, promising preliminary results, shift towards personalized medicine. The limitations are that a phase 1 trial is limited to a safety feasibility study that requires validation in the long run, potential off-target effects, complexity, and accessibility of the procedure.
Lattanzi et al., 20216 Pre-clinical experimental study Strengths of the study include high correction efficiency as it provides up to 60% allelic correction and 20% gene correction, potential for clinical translation. Limitations of the studies are its pre-clinical stage complex manufacturing process, Variability in human responses, and potential off-target effects.

SCD, sickle cell disease.